Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENSOR: Cinacalcet dosing timing in hemodialysis
NCT00117052Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2004
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Amgen. Primary endpoint: Proportion of subjects with PTH less than or equal to 300 pg/mL at 21 weeks. Started Sep 2004; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00117052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117052.